BiotechTube

Nivolumab + Docetaxel/Paclitaxel

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Cancer

Conditions

Esophageal Cancer

Trial Timeline

Dec 14, 2015 → Oct 23, 2020

NCT ID
NCT02569242

About Nivolumab + Docetaxel/Paclitaxel

Nivolumab + Docetaxel/Paclitaxel is a phase 3 stage product being developed by Ono Pharmaceutical for Esophageal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02569242. Target conditions include Esophageal Cancer.

What happened to similar drugs?

19 of 20 similar drugs in Esophageal Cancer were approved

Approved (19) Terminated (2) Active (1)
✅rabeprazole and pantoprazoleEisaiApproved
✅rabeprazole + pantoprazoleEisaiApproved
✅Placebo + CisaprideJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02569242Phase 3Completed

Competing Products

20 competing products in Esophageal Cancer

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPhase 1
29
FamotidineAstellas PharmaPhase 2/3
38
ASP546CAstellas PharmaPhase 1/2
39
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
JS001 + nab-paclitaxel + Cisplatin + CarboplatinSun PharmaceuticalPhase 2
42
E3810 + E3810 + PlaceboEisaiPhase 3
40